Search

Yansha Song,1,* Xiaocen Wang,1,* Ke Lang,1,* Tingting Wei,1 Jinlong Luo,1 Yuanlin Song,1,2 Dong Yang1,2 1Department of Pulmonary and Critical Care Medicine, Zhongshan Hospital, Fudan University, Shanghai, People’s Republic of China; 2Shanghai Key Laboratory of Lung Inflammation and Injury, Shanghai, People’s Republic of China*These authors contributed equally to this workCorrespondence: Dong Yang; Yuanlin Song, Department of Pulmonary and Critical Care Medicine, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, People’s Republic of China, Tel +86 21 64041990, Email yang.dong@zs-hospital.sh.cn; song.yuanlin@zs-hospital.sh.cnIntroduction: There were few studies on the mortality of severe community-acquired pneumonia (SCAP) in elderly people. Early prediction of 28-day mortality of hospitalized patients will help in the clinical management of elderly patients (age ≥ 65 years) with SCAP, but a prediction model that is reliable and valid is still lacking.Methods: The 292 elderly patients with SCAP met the criteria defined by the American Thoracic Society from 33 hospitals in China. Clinical parameters were analyzed by the use of univariable and multivariable logistic regression analysis. A nomogram to predict the 28-day mortality in elderly patients with SCAP was constructed and evaluated using the area under the receiver operating characteristic curve (AUC) and internally verified using the Bootstrap method.Results: A total of 292 elderly patients (227 surviving and 65 died within 28 days) were included in the analysis. Age, Glasgow score, blood platelet, and blood urea nitrogen values were found to be significantly associated with 28-day mortality in elderly patients with SCAP. The AUC of the nomogram was 0.713 and the calibration curve for 28-day mortality also showed high coherence between the predicted and actual probability of mortality.Conclusion: This study provides a nomogram containing age, Glasgow score

Wei T, Wang X, Lang K, et al. J Inflamm Res. 2022;15:1259–1271. The authors have advised that the funding statement on page 1270 is incorrect. An additional funding source was inadvertently omitted by the authors. The text “This work was supported, in part, by National Natural Science Foundation of China (project number 81970069;82170091); Smart Healthcare Project of Zhongshan Hospital, Fudan University (project number 2020ZHZS18)” should read “This work was supported, in part, by State’s Key Project of Research and Development Plan (2017YFC1310602, 2017YFC1310600); National Natural Science Foundation of China (project number 81970069; 82170091); and Smart Healthcare Project of Zhongshan Hospital, Fudan University (project number 2020ZHZS18)”. The authors apologize for this omission. Read the original article

Tingting Wei,* Xiaocen Wang,* Ke Lang,* Cuicui Chen, Yansha Song, Jinlong Luo, Zhaolin Gu, Xianglin Hu, Dong Yang Department of Pulmonary and Critical Care Medicine, Zhongshan Hospital, Fudan University, Shanghai, People’s Republic of China*These authors contributed equally to this workCorrespondence: Dong Yang; Xianglin Hu, Email yang.dong@zs-hospital.sh.cn; xianglinhero@163.comRationale: Eosinophilic inflammation is related to the progression and outcomes of acute exacerbation of chronic obstructive pulmonary disease (AECOPD). Till now, few studies have focused on low EOS in AECOPD.Objective: To reveal the clinical characteristics, therapeutic responses and prognosis of patients hospitalized of AECOPD with low EOS.Methods: The electronic database of Zhongshan Hospital, Fudan University was used. Cohort 1 included 608 patients with hospitalized AECOPD. Study population 2 consisted of 166 patients with AECOPD admission at least twice. Impact of low EOS on NIMV treatment, length of hospital stays and 12-month AECOPD-related readmission were analyzed with multivariable logistic regression model. Thirty-five hospitalized AECOPD patients were prospectively recruited as cohort 3 to explore the association between EOS and other immune cells using Spearman correlation coefficient for ranked data.Results: EOS level was suppressed on admission in AECOPD patients, and significantly improved after hospitalized treatment (P < 0.05). For inflammatory markers, leucocytes, neutrophils and lactate dehydrogenase levels were higher, while lymphocytes, monocytes and interleukin-6 levels were lower in the low-EOS group than those in the non-low EOS group (P < 0.05). Low EOS (EOS < 50 cells/μL) was an independent risk factor of NIMV use (OR = 1.86, 95% CI = 1.26 ∼ 2.73). The EOS percentage was positively correlated with the T cell percentage (r = 0.46, P < 0.05) and negatively correlated with the natural killer cell percentage (r = &a

Jing Luo,1–3 Sainan Hu,4 Tingting Wei,1–3 Jifeng Sun,1–3 Ningbo Liu,1–3 Jun Wang1–3 1Department of Radiation Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, 2Key Laboratory of Cancer Prevention and Therapy, 3Tianjin’s Clinical Research Center for Cancer, Tianjin 300060, China; 4Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing 210000, China Purpose: Plasma TGF-β1 protein levels reportedly may predict the treatment outcomes of lung cancer. We hypothesized that in patients with lung cancer treated with radiation therapy (RT), TGF-β1 levels may correlate with the percentages of CD4+ T cells, CD8+ T cells, and the CD4+/CD8+ T cell ratio in peripheral blood. Patients and methods: Eighty-two lung cancer patients satisfied the inclusion criteria. Platelet-poor plasma was obtained before RT, at the second and fourth weeks during RT, and at the end of RT (pre-, during-, and post-RT, respectively). TGF-β1 was measured via ELISA, while recording the percentages of lymphocyte subsets in peripheral blood. Short-term efficacy was categorized as complete response, partial response, stable disease, or progressive disease. Results: Patients who had significantly lower TGF-β1 protein levels after RT than pre-RT seemed to have a better short-term effect (P<0.05) than those who had higher TGF-β1 levels. There was a significant association between the TGF-β1 levels and percentages of CD4+ T cells, CD8+ T cells, or CD4+/CD8+ T cell ratio during and at the end of RT. Changes in CD3+ T cells, B cells, or natural killer cells were not statistically related to the changes in TGF-β1 levels. Conclusion: Lung cancer patients with TGF-β1 levels in plasma after RT that are below pre-RT levels may experience better

学位の種類: 博士（工学）. 報告番号: 甲第4183号. 学位記番号: 新大院博（工）甲第440号. 学位授与年月日: 平成28年3月23日, 博士（工学）, 新潟大学